SARS-CoV-2 seroprevalence on the north coast of Peru: A cross-sectional study after the first wave
- Luz M. Moyano,
- Angie K. Toledo(corresponding author),
- Jenny Chirinos,
- Percy Mcquen Vilchez Barreto,
- Sofia Cavalcanti,
- Ricardo Gamboa
- Universidad César Vallejo,
- Dirección Regional de Salud de Tumbes,
- Unidad de Medicina Legal I Contralmirante Villar,
- ,
- Universidad Peruana Cayetano Heredia,
- Universidad Peruana Cayetano Heredia, Centro de Salud Global Tumbes
Open access
Publication Information
Output type
Original language
EnglishArticle number
e0010794Journal (Volume, Issue Number)
PLoS Neglected Tropical Diseases (Volume 17, Issue 6 June)Publication milestones
- Published - 06/2023
Publication status
ISSN
1935-2727Publication IDs
- Scopus: 85164297287
- PubMed: 37379355
Abstract
Background Peru had the second-highest number of COVID-19 cases in Latin America. After the first wave, Peru registered more than 900,000 cases of COVID-19 and more than 36,000 confirmed deaths from the disease. Tumbes, a border area with poor sanitation and not enough water, had the fifth highest death rate. The cross-sectional analytic study aimed: a) to assess seroprevalence of COVID-19 after the first wave; b) to assess sociodemographic determinants and symptoms associated with a positive COVID-19 antibody lateral flow test. Methodology/principal findings We performed this study between November 11th and November 30th, 2020, in an informal settlement in Tumbes. Individuals older than two years were invited to participate in a systematic random sample from one in every four households. Finger-prick blood samples were collected, and a census and symptom survey were applied. Within the chosen house, one adult over 18 years of age was chosen for a PCR-RT molecular test. Overall seroprevalence was 25.59%, adjusted seroprevalence was 24.82% (95%CI 22.49–27.25). Women had higher adjusted seroprevalence (28.03% vs 21.11%; 95% CI 24.83–31.41, p = 0.002). Symptoms as fever (PR 1.89: 95% CI 1.44–2.48, p<0.001), general discomfort (PR 1.67; 95% CI 1.23–2.26, p = 0.001), cough (PR 2.0; 95% CI 1.60–2.50, p<0.001), nasal congestion (PR 1.46; 95% CI 1.03–2.09, p = 0.036), respiratory distress (PR 1.64; 95% CI 1.04–2.56, p = 0.031), headache (PR 1.54; 95% CI 1.09–2.17, p = 0.014), anosmia (PR 1.78; 95% CI 1.01–3.14, p = 0.046) and ageusia (PR 2.31; 95% CI 1.48–3.61, p<0.001) were associated with a positive covid-19 antibody lateral flow test. Conclusions/significance The COVID-19 transmission and distribution were highlighted by this cross-sectional study. The data will help the Ministry of Health improve its monitoring, surveillance, and monitoring of respiratory community sequelae in the future.
Publication metrics
Metrics
PlumX, opens in new tab
Sustainable Development Goals
- SDG 3 Good Health and Well
